BRIDGING HTA AGENCIES ACROSS EUROPE: A SYSTEMATIC APPROACH TO CATEGORIZE EVOLVING AGENCIES

被引：0

作者：

Nagy, L. ^{[1
]}

Kamal-Bahl, S. ^{[2
]}

Brandtmueller, A. ^{[3
]}

机构：

[1] MSD Pharma Hungary Ltd, Budapest, Hungary

[2] Merck & Co Inc, Sumneytown Pike, PA USA

[3] MSD Pharma Hungary, Budapest, Hungary

来源：

VALUE IN HEALTH | 2013年 / 16卷 / 03期

关键词：

D O I：

10.1016/j.jval.2013.03.1375

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A268 / A268

页数：1

共 18 条

[1] A SYSTEMATIC FRAMEWORK FOR COMPARING METHODS, PROCEDURES, AND IMPACT ACROSS HTA AGENCIES
Schwarzer, R.
Siebert, U.
[J]. VALUE IN HEALTH, 2008, 11 (06) : A337 - A338
[2] ACCEPTANCE OF SURROGATE ENDPOINTS BY HTA AGENCIES IN EUROPE
Es-Skali, I. J.
Nijhuis, T.
[J]. VALUE IN HEALTH, 2013, 16 (07) : A484 - A484
[3] Differences In HTA Acceptance Rates Across Disease Areas: A Comparison Between Four HTA Agencies
Vadlamudi, N. K.
Griffiths, E. A.
[J]. VALUE IN HEALTH, 2016, 19 (03) : A287 - A287
[4] REIMBURSEMENT DECISION LANDSCAPE FOR ORPHAN DRUGS ACROSS SIX HTA AGENCIES
Mittal, L. K.
Banerjee, P.
Kapoor, A.
Ligade, V. S.
[J]. VALUE IN HEALTH, 2016, 19 (03) : A257 - A257
[5] THE HEALTH RELATED QUALITY OF LIFE DATA (HRQOL) FOR HEALTH TECHNOLOGY ASSESSMENT (HTA) PROCESS IN EUROPE: THEIR UTILIZATION AND IMPACT ON OPINIONS ACROSS HTA AGENCIES
Stamenkovic, S.
[J]. VALUE IN HEALTH, 2011, 14 (07) : A467 - A467
[6] DIFFERENCES IN GUIDANCE ON PRO EVIDENTIARY REQUIREMENTS ACROSS KEY EUROPEAN HTA AGENCIES
Chassany, O.
van Engen, A.
Lai, L.
Borhade, K.
Ravi, M.
Harnett, J.
Chen, C., I
Quek, R. G. W.
[J]. VALUE IN HEALTH, 2022, 25 (07) : S505 - S505
[7] Three worlds of health technology assessment: explaining patterns of diffusion of HTA agencies in Europe
Loblova, Olga
[J]. HEALTH ECONOMICS POLICY AND LAW, 2016, 11 (03) : 253 - 273
[8] TRENDS AND KEY DECISION DRIVERS FOR REJECTING AN ORPHAN DRUG SUBMISSION ACROSS FIVE DIFFERENT HTA AGENCIES
Mardiguian, S.
Stefanidou, M.
Sheppard, F.
[J]. VALUE IN HEALTH, 2014, 17 (07) : A438 - A438
[9] GLOBAL ONCOLOGY ACCESS - THE RELATIVE DIFFICULTY OF REIMBURSEMENT ACROSS FOUR HEALTH TECHNOLOGY ASSESSMENT (HTA) AGENCIES
Nguyen, K.
Forsythe, A.
Azimpour, K.
Vu, B. K.
Tomaras, D.
[J]. VALUE IN HEALTH, 2020, 23 : S68 - S68
[10] AN EVALUATION OF SPECIAL CONSIDERATIONS IN THE ASSESSMENT AND DECISION-MAKING PROCESSES ACROSS HTA AGENCIES FOR DRUGS FOR RARE DISEASES
Harricharan, S.
Musat, M.
Wiltshire, L.
Hubscher, E.
[J]. VALUE IN HEALTH, 2023, 26 (06) : S5 - S5

← 1 2 →